Abstract
We analyzed the ability of the BaF3 cell line bioassay to select patients with biologically inactive GH. We first evaluated the biological response of the Ba/F3-hGHR cells to rhGH additional doses from 10 to 5000 pg/ml. The concentration points corresponding to the linear part of the curve were selected. We then analyzed a group of sera, diluted like the standard, including the entire range of GH concentrations that can be analyzed by bioassay. The serum/standard area below the curve ratio was calculated. Serum GH immunoactivity determined by IMMULITE/ GH bioactivity ratios was calculated. Our experimental data showed that GH-bioactivity/GH-immunoactivity ratios below 0.303 are indicative of a bioinactive GH molecule. This bioassay would recognize only extreme cases of GH bioinactivity, and it would not be a useful tool in the search for patients with altered forms of GH.
| Original language | English |
|---|---|
| Pages (from-to) | 783-788 |
| Number of pages | 6 |
| Journal | Journal of Pediatric Endocrinology and Metabolism |
| Volume | 23 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2010 |
Keywords
- Bioassay
- Cell line
- Gene mutation
- GH biological activity
- Growth hormone
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
- Pediatrics, Perinatology, and Child Health